Comparative Pharmacology
Head-to-head clinical analysis: ANDROID F versus TESTOSTERONE CYPIONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID F versus TESTOSTERONE CYPIONATE.
ANDROID-F vs TESTOSTERONE CYPIONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fingolimod is a sphingosine 1-phosphate receptor modulator that sequesters lymphocytes in lymph nodes, reducing central nervous system immune cell infiltration.
Testosterone cypionate is a synthetic androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle growth, and secondary sexual characteristic development. It also suppresses gonadotropin release via negative feedback.
Adults: 1 tablet (methyltestosterone 2.5 mg, ethinyl estradiol 0.025 mg) orally once daily, with food.
Intramuscular injection of 50-400 mg every 2-4 weeks, typically 200 mg every 2 weeks or 400 mg every 4 weeks.
None Documented
None Documented
2.5-3.5 hours (terminal half-life); oral administration may require multiple daily doses for stable levels.
Approximately 8 days (terminal elimination half-life of testosterone cypionate after intramuscular injection; due to slow release from oil depot, effective half-life in muscle is ~8 days with a longer terminal phase up to 3 weeks)
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); small amount biliary/fecal.
Renal (90% as glucuronide and sulfate conjugates), fecal (10%)
Category C
Category D/X
Androgen/Estrogen Combination
Androgen